Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice

Journal of Bone and Mineral Research

Volumn 22, Issue 1, 2007, Pages 55-63

  Samadfam, Rana ^a   Xia, Qingwen ^a   Goltzman, David ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Alendronate; Bone turnover; Osteoprotegerin; PTH; Skeletal coupling

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALENDRONIC ACID; OSTEOPONTIN; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BONE DENSITY; BONE GROWTH; BONE METABOLISM; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FEMUR; HISTOLOGY; LUMBAR SPINE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; PROTEIN BLOOD LEVEL; SKELETON; SKELETON RADIOGRAPHY; TRABECULAR BONE;

ALENDRONATE; ANIMALS; BONE AND BONES; FEMALE; FEMUR; MICE; MICE, INBRED C57BL; OSTEOPROTEGERIN; OVARIECTOMY; PARATHYROID HORMONE; SPINE;

EID: 33845934478     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060915     Document Type: Article

References (32)

1. Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ 2005 JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 7:1265-1274.
2. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Olombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
3. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to RANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.
4. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831.
5. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610.
6. Gasser JA, Kneissel M, Thomsen JS, Mosekilde L 2000 PTH and interactions with bisphosphonates. J Musculoskelet Neuronal Interact 1:53-56.
7. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
8. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226.
9. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M 2003 New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology 144:2008-2015.
10. Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R 1998 Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13:1051-1055.
11. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4304.
12. Valenta A, Roschger P, Fratzl-Zelman N, Kostenuik PJ, Dunstan CR, Fratzl P, Klaushofer K 2005 Combined treatment with PTH (1-34) and OPG increases bone volume and uniformity of mineralization in aged ovariectomized rats. Bone 37:87-95.
13. Miao D, Bai X, Panda D, McKee M, Karaplis A, Goltzman D 2001 Osteomalacia in Hyp mice is associated with abnormal Phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142:926-939.
14. Miao D, Scutt A 2002 Recruitment, augmentation and apoptosis of rat osteoclasts in 1,25-(OH)2D3 response to short-term treatment with 1,25-dihydroxyvitamin D3 in vivo. BMC Musculoskelet Disord 3:16-26.
15. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-561.
16. Porras AG, Holland SD, Gertz BJ 1999 Pharmacokinetics of alendronate. Clin Pharmacokinet 36:315-328.
17. Miao D, Tong XK, Chan GK, Panda D, McPherson PS, Goltzman D 2001 Parathyroid hormone-related peptide stimulates osteogenic cell proliferation through protein kinase C activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 276:32204-32213.
18. Hodsman AB, Steer BM 1993 Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiescent cancellous surfaceson quiescent cancellous surfaces. Bone 14:523-527.
19. Dobnig H, Turner RT 1995 Evidence that intermittent treatment with parathyroid-hormone increases bone-formation in adult-rats by activation of bone lining cells. Endocrinology 136:3632-3638.
20. Carpio L, Gladu J, Goltzman D, Rabbani SA 2001 Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Physiol Endocrinol Metab 281:E489-E499.
21. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC 2002 Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282:1-17.
22. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446.
23. Iida-Klein A, Zhou H, Lu SS, Levine LR, Ducayen-Knowles M, Dempster DW, Nieves J, Lindsay R 2002 Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J Bone Miner Res 17:808-816.
24. Iida-Klein A, Hughes C, Lu SS, Moreno A, Shen V, Dempster DW, Cosman F, Lindsay R 2006 Effects of cyclic versus daily hPTH (1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. J Bone Miner Res 21:274-282.
25. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442.
26. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370-1375.
27. Koh AJ, Demiralp B, Neiva KG, Hooten J, Nohutcu RM, Shim H, Datta NS, Taichman RS, McCauley LK 2005 Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584-4596.
28. Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M, Lehenkari P 2005 In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97:382-391.
29. von Knoch F, Jaquiery C, Kowalsky M, Schaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS 2005 Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 26:6941-6949.
30. Kubota K, Sakikawa C, Katsumata M, Nakamura T, Wakabayashi K 2002 Platelet-derived growth factor BB secreted from osteoclasts acts as an osteoblastogenesis inhibitory factor. J Bone Miner Res 17:257-265.
31. Martin TJ 2004 Does bone resorption inhibition affect the anabolic response to parathyroid hormone? Trends Endocrinol Metab 15:49-50.
32. Howard GA, Bottemiller BL, Turner RT, Rader JI, Baylink DJ 1981 Parathyroid hormone stimulates bone formation and resorption in organ culture: Evidence for a coupling mechanisms. Proc Natl Acad Sci USA 78:3204-3208.